<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565123</url>
  </required_header>
  <id_info>
    <org_study_id>LF- 12/2003</org_study_id>
    <nct_id>NCT00565123</nct_id>
  </id_info>
  <brief_title>Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis</brief_title>
  <official_title>A Single- Centre, Randomised Study Of The Clinical And Microbiological Efficacy Of Decreasing The Dosage Of Levofloxacin 0,5% Eye Drops As Compared To Standard Eye Drop Dosage In Patients With Bacterial Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laser Microsurgery Centre, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Katedra I Klinika Okulistyki II Wydz. Lek. AM w Warszawie,</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital No 1 Wroclaw</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MedSource Polska</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laser Microsurgery Centre, Poland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the clinical and microbiological efficacies of three
      times daily administration of levofloxacin 0,5% eye drops as compared to the more frequent
      dosing (up to 8 times a day during the first 2 days and up to 4 times a day during the next 3
      days) in patients with bacterial conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint was the clinical cure.</measure>
    <time_frame>7(+-1) days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary efficacy end point was the microbiological eradication.</measure>
    <time_frame>7(+-1) days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Bacterial Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Classical dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% levofloxacin eye drops</intervention_name>
    <description>0.5% levofloxacin eye drops three times daily to each eye for 5 days</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% levofloxacin eye drops</intervention_name>
    <description>0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients between 18 and 70 years of age

          -  Patients with Conjunctivitis (defined as the presence of three cardinal signs:
             conjunctival discharge, bulbar conjunctival injection and palpebral conjunctival
             injection)

          -  Patients who have given and signed informed consent

          -  The ability and willingness to comply with all study procedures

        Exclusion Criteria:

          -  Insulin Dependent Diabetes Mellitus (IDDM)

          -  Patients with keratitis or hordeolum

          -  Glaucoma

          -  Sjogren's Syndrom and &quot;Sick Eye's Syndrom&quot;.

          -  Ectropion, entropion;

          -  Using contact lenses during the study

          -  Poor visual acuity in the other eye

          -  Prior and concurrent concomitant treatment glycocorticosteroids, immunosupressive
             therapy, if these treatments have not stopped at least 3 months prior to the start of
             the study;

          -  Concurrent use of non- steriodal anti- inflammatory drugs (NSAIDs), with the exception
             of low- dose aspirin. (see par. 11.5)

          -  Prior and concurrent systemic antibiotic treatment during last 7 days before the
             beginning the study.(see par. 11.5)

          -  Concurrent other eye drops

          -  All ocular surgeries which were performed less than 6 months before the beginning of
             the study.

          -  Any clinical condition, which, in the opinion of the investigator would not allow safe
             completion of the protocol.

          -  History of any malignancy within the past 5 years prior to study entry, except basal
             cell or squamous cell skin carcinoma.

          -  Hypersensitivity to fluoroquinolons and benzalkonium chloride;

          -  Intended or ascertained pregnancy or lactation;

          -  Participation in a clinical trial within last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerzy Szaflik, MD,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laser Microsurgery Centre; Department of Ophthalmology, Medical University of Warsaw</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centrum Mikrochirurgii Oka Laser</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-131</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2007</study_first_submitted>
  <study_first_submitted_qc>November 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2007</study_first_posted>
  <last_update_submitted>November 28, 2007</last_update_submitted>
  <last_update_submitted_qc>November 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2007</last_update_posted>
  <keyword>bacterial conjunctivitis levofloxacin fluoroquinolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

